

|   |   |                        |
|---|---|------------------------|
|  | <b>O-FIS Qualitätsmanagementsystem</b><br>Formblatt<br><b>Collection and Cohort Profile</b> | CL312<br>Seite 1 von 2 |
|---|---|------------------------|

## 1. General Information

|                               |  |
|-------------------------------|--|
| <b>Cohort ID</b>              | 5006_21  |
| <b>Title (Study Name)</b>     | COVAC-DM Study   |
| <b>Principal investigator</b> | Prof. Harald Sourij  |
| <b>Contact information</b>    | <a href="mailto:pm-biobank@medunigraz.at">pm-biobank@medunigraz.at</a> |
| <b>Funding agency</b>         | FWF decision pending   |

## 2. Description

It is unknown, if people with established diabetes mellitus type 1 or type 2 display a reduced humoral immune response following COVID-19 vaccination as compared to people without this condition. In this study, we prospectively investigate antibody response in people with diabetes, following the first and second dose of vaccination (predominantly mRNA vaccine) as well as 12 months thereafter.

## 3. Details

|   |   |       |
|---|---|-------|
| <b>ICD 10/O codes / Healthy</b>             | E10, E11  |       |
| <b>Key words</b>                            | diabetes mellitus type 1, diabetes mellitus type 2, COVID-19, COVID-19 vaccine  |       |
| <b>Collection / Cohort size</b><br>12/2022  | 7.121 aliquots from 150 patients  |       |
| <b>Informed Consent (IC)</b>                | <input checked="" type="checkbox"/> Broad Biobank IC  |       |
|   | <input checked="" type="checkbox"/> Specific Study IC   |       |
| <b>Status</b>                               | <input type="checkbox"/> In progress / compl. date:   |       |
|   | <input checked="" type="checkbox"/> Completed   |       |
| <b>Inclusion criteria</b>                   | <b>Age distribution</b>   | 18+   |
|   | <b>Sex distribution (f:m)</b>   | 40:60 |
|   | <b>Others</b>   | ----  |
| <b>Earliest access</b>                      | As of now   |       |
| <b>Quality-standards</b>                    | <input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)  |       |
| <b>Associated publications / references</b> | <p><u>Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study</u><br/>           Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, Kojzar H, Kleinhapfl B, Pferschy PN, Mader JK, Cvirn G, Goswami N, Wachsmuth N, Eckstein ML, Müller A, Abbas F, Lenz J, Steinberger M, Knoll L, Krause R, Stradner M, Schlenke P, Sareban N, Prietl B, Kaser S, Moser O, Steinmetz I, Sourij H; COVAC-DM study group.<br/> <a href="https://pubmed.ncbi.nlm.nih.gov/34984802/">https://pubmed.ncbi.nlm.nih.gov/34984802/</a></p> <p><u>Impact of COVID-19 Vaccination on Glycemia in Individuals With Type 1 and Type 2 Diabetes: Substudy of the COVAC-DM Study.</u><br/>           Aberer F, Moser O, Aziz F, Sourij C, Ziko H, Lenz J, Abbas F, Obermayer AM, Kojzar H, Pferschy PN, Müller A, Unteregger C, Leitner M, Banfic T, Eckstein ML, Wachsmuth N, Kaser S, Mader JK, Tripolt NJ, Sourij H.<br/> <a href="https://pubmed.ncbi.nlm.nih.gov/34848490/">https://pubmed.ncbi.nlm.nih.gov/34848490/</a></p> |       |

#### 4. Material available (aliquot size) and storage conditions

|                 |  |   |
|-----------------|--|---|
| <b>Material</b> | <input checked="" type="checkbox"/> Serum (580 µl)             | <input checked="" type="checkbox"/> -80°C |
|                 | <input checked="" type="checkbox"/> EDTA plasma (580 µl)       | <input checked="" type="checkbox"/> -80°C |
|                 | <input checked="" type="checkbox"/> Na-Citrate plasma (235 µl) | <input checked="" type="checkbox"/> -80°C |
|                 | <input checked="" type="checkbox"/> Saliva                     | <input checked="" type="checkbox"/> -80°C |

|  |  |
|--|--|
| <b>Dokument erstellt</b> (tt/mm/yyyy):<br>16/06/2021 | <b>Letzte inhaltliche Aktualisierung</b> (tt/mm/yyyy):<br>04/08/2023 |
|--|--|